Miruvor
Sign up
The short answer

What studies of Rivaroxaban (Xarelto) found

2papers on Rivaroxaban (Xarelto)
171people in 1 study testing Rivaroxaban (Xarelto) alone
1randomised trial, the strongest kind of study

At a glance, by condition

Long COVID: B May help

Based on the strongest evidence, the randomised trial (low certainty), for quality of life.

2 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Rivaroxaban (Xarelto) may help for long COVID, but the evidence is still limited. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 2 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. Rivaroxaban (Xarelto) · Long COVID is hereB
    May helpImprovement, low certainty
  3. C
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Symptoms

Fatigue1 study · 171 people took Rivaroxaban (Xarelto) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; no confidence interval shows an important benefit is ruled out.

The randomised trial778 randomised · 668 analysed · 12 weeks (primary endpoint); 24 weeks (secondary endpoint, 12 weeks after drug cessation) · 10 mg, once daily

No clear difference in fatigue.

The evidence is very uncertain about the effect of rivaroxaban (Xarelto) on fatigue in long COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • No confidence interval shows an important benefit is ruled out
See the 1 study
  1. Efficacy and safety of rivaroxaban, colchicine, and famotidine-loratadine with specialist supportive clinical care for fatigue in patients with post-COVID-19 condition in the UK: a multisite, open-label, randomised controlled trial. (2026)

    People in the study
    778 randomised · 668 analysed
    Dose
    10 mg, once daily
    Outcome
    12-week FAS score Fatigue Assessment Scale
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    High
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    High

Daily life and health overall

Quality of life1 study · 171 people took Rivaroxaban (Xarelto) Improvement B
Low certainty

Why this grade: Improvement, low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight.

The randomised trial778 randomised · 668 analysed · 12 weeks (primary endpoint); 24 weeks (secondary endpoint, 12 weeks after drug cessation) · 10 mg, once daily

Quality of life improved more than in the comparison group.

Rivaroxaban (Xarelto) may improve quality of life in long COVID. Improvement · low certainty B

  • High risk of bias (RoB 2) in the results that carry most of the weight
See the 1 study
  1. Efficacy and safety of rivaroxaban, colchicine, and famotidine-loratadine with specialist supportive clinical care for fatigue in patients with post-COVID-19 condition in the UK: a multisite, open-label, randomised controlled trial. (2026)

    People in the study
    778 randomised · 668 analysed
    Dose
    10 mg, once daily
    Outcome
    EQ-VAS score at 12 weeks EQ-5D-5L visual analogue scale
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    High
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Low

Side effects

No study of this treatment alone reported side effects we could read.

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    10 mg at the start

  2. 2Top dose

    Most often 10 mg (1 of 1 studies)

All papers

  1. Efficacy and safety of rivaroxaban, colchicine, and famotidine-loratadine with specialist supportive clinical care for fatigue in patients with post-COVID-19 condition in the UK: a multisite, open-label, randomised controlled trial.2026 · randomised trial · 778 randomised · 668 analysed
    Summary

    This multisite, open-label, randomised controlled trial asked whether repurposed drugs reduce fatigue in adults with long COVID who had not been hospitalised with COVID-19. It took place across 12 UK NHS specialist long COVID care clinics. 778 participants were randomly assigned 1:1:1:1 to colchicine 500 μg twice daily (n=192), famotidine 40 mg with loratadine 10 mg once daily (n=193), rivaroxaban 10 mg once daily (n=197), or no drug (n=196) for 12 weeks; all received usual care. The primary measure was the Fatigue Assessment Scale (FAS, 10 to 50, higher worse) at 12 weeks, with a 24-week FAS secondary endpoint. 668 participants had a calculable 12-week FAS score (160 colchicine, 174 famotidine–loratadine, 171 rivaroxaban, 163 no drug). Mean FAS fell within every group: 4.4 points with colchicine, 4.8 with famotidine–loratadine, 4.4 with rivaroxaban, and 3.3 with no drug. Adjusted differences versus no drug were –1.49 points (95% CI –2.92 to –0.06; p=0.041) for colchicine, –1.48 (–2.88 to –0.08; p=0.038) for famotidine–loratadine, and –1.06 (–2.47 to 0.35; p=0.139) for rivaroxaban. At 24 weeks, differences were –0.043 (p=0.96), 0.34 (p=0.66), and 0.04 (p=0.96). EQ-VAS at 12 weeks was higher by 4.13, 4.84, and 3.5 points in the colchicine, famotidine–loratadine, and rivaroxaban groups. Adverse events were reported by 57 of 192, 51 of 193, 70 of 197, and 21 of 196 participants; ten serious adverse events occurred in eight participants, five in three rivaroxaban participants. The authors state limitations including inability to exclude placebo effects or expectation bias in the open-label trial.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime